On this critical COVID-19 pandemic times, each social agent must give its best and show social commitment. Our best way to support the health world in this situation is with our recombinant nucleoprotein antigen for SARS-CoV (NP-CTD), the most trustable method for a fast and effective COVID-19 early detection.
We are happy to announce that Rekom Biotech will be a supplier of raw material for COVID-19 detection to the Indian company whose Covid IgG ELISA kit is approved by the Indian government.
The Spanish Centre for the Development of Industrial Technology (CDTI) has chosen to award a grant to R&D and investment projects in order to face the health emergency declared due to COVID-19. The selected projects allow the following: increase the availability of emergency products; contribute to improve the treatment of the disease, as well as the diagnosis and clinical management of patients infected by SARS-CoV-2; contribute to the design, development and implementation of public health measures to respond effectively to the epidemic.
The total amount of projects presented reached the number of 577 and only 9 of them were selected, including Rekom Biotech's one - "PREPARATION OF BIOMARKERS FOR DETECTION OF COVID-19 AND FOR USE IN RAPID TESTS TO MEASURE SEROPREVALENCE IN THE POPULATION".
This week, 16th may, 2018, the project "MULTIFLOW" subsidized by the Center for Industrial Technological Development under the FEDER INNTERCONECTA program and carried out by the companies Vitro, Master Diagnostica, Destina Genómica and Rekom Biotech has concluded. The closure of the project was carried out in Seville, in the Vitro facilities. The multidisciplinary team formed by the "MULTIFLOW" consortium has successfully completed all the technical objectives established in the project. From Rekom Biotech we thank our partners in the consortium for the great work and collaboration environment that has characterized the project since its beginnings.
Our commitment to ensure the highest quality level in the design and production of recombinant antigens continues after the implementation of the ISO:9001-2015 Standard.
Rekom Biotech signed a distribution agreement with the Japanese company Tokyo Future Style, Inc. The agreement was concluded on February 25th, 2014 and covers the territories of Japan, South Korea and Taiwan.
The new distributor Tokyo Future Style, Inc. will be in charge of introducing Rekom Biotech’s products to this great potential market which already exhibits high growth rates.